Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 1.00 |
| ▸ | HPGDS | O60760 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28402826 | 0.94 | NPY5R (0.88) | NPY5RHPGDSKDM4ESMN1; SMN2LDHA | |
| SCHEMBL2840665 | 0.86 | NPY5R (0.75) | NPY5RHPGDSKDM4ESMN1; SMN2LDHA | |
| SCHEMBL2319610 | 0.86 | HPGDS (0.79) | NPY5RHPGDSKDM4ESMN1; SMN2LDHA | |
| SCHEMBL28763036 | 0.86 | NPY5R (0.74) | NPY5RHPGDSKDM4ESMN1; SMN2CYP19A1 | |
| SCHEMBL724250 | 0.84 | NPY5R (0.72) | NPY5RHPGDSKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL28399047 | 0.83 | NPY5R (0.71) | NPY5RHPGDSSMPD3MAPK13RAF1 | |
| SCHEMBL2689052 | 0.81 | NPY5R (0.69) | NPY5RKDM4ESMN1; SMN2LDHAEPHX2 | |
| SCHEMBL2313376 | 0.81 | NPY5R (0.67) | NPY5RHPGDSKDM4ESMN1; SMN2LDHA | |
| SCHEMBL31305589 | 0.81 | NPY5R (0.68) | NPY5RHPGDSKDM4EKMT2ASMPD3 | |
| SCHEMBL28402852 | 0.81 | NPY5R (0.82) | NPY5RHPGDSKDM4ESMN1; SMN2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12427179-B2 | Compositions and methods for diagnosis and treatment of neurodegenerative diseases | Epitracker, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4590287-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | Brightseed, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | BRIGHTSEED, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250000804-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMA (US) LLC | 2025-01-02 | — | — | US | disclosed |
| US-20240307336-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240277649-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | EPITRACKER INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4410285-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF METABOLIC SYNDROME | Government Of The United States Of America As Represented By The Secretary Of the Navy (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410380-A2 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | Anji Pharmaceuticals Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11992473-B2 | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity | Epitracker, Inc. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20230293491-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4234038-A2 | COMPOSITIONS COMPRISING HEPTADECANOIC ACID FOR THE TREATMENT OF INFLAMMATION AND RELATED CONDITIONS | The United States Of America As Represented By The Secretary Of The Navy (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3562480-B1 | COMPOSITIONS COMPRISING HEPTADECANOIC ACID FOR THE TREATMENT OF INFLAMMATION AND RELATED CONDITIONS | US NAVY (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| WO-2022098572-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | Epitracker, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-4822805-A | ANTIINFLAMMATORY AGENTS, CARDIOTONIC AGENTS, ANTIPLATELET AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| CN-87105680-A | Imidazolium compounds and preparation method thereof and comprise the pharmaceutical composition of this compound | — | 1988-04-27 | — | — | CN | disclosed |
| EP-0257897-A1 | Imidazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | NPY5R 2898/4885HPGDS 51/4885KDM4E 4710/4885 |
| US-20230293491-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | BHMT, FTH1, HBG1 | NPY5R 1109/4885HPGDS 257/4885KDM4E 4417/4885 |
| US-20250000804-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | SLC5A2, SLC10A1, GPR119 | NPY5R 912/4885HPGDS 1138/4885KDM4E 3240/4885 |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | FABP2, VIP, SI | NPY5R 528/4885HPGDS 174/4885KDM4E 4072/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | NPY5R 723/4885HPGDS 2156/4885KDM4E 2303/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | NPY5R 723/4885HPGDS 2156/4885KDM4E 2303/4885 |
| US-20240277649-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | NPY5R 715/4885HPGDS 191/4885KDM4E 3869/4885 |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | FABP2, GPR119, PNLIP | NPY5R 2671/4885HPGDS 1333/4885KDM4E 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.